ATLAS Trial: 10 years vs. 5 years of tamoxifen in patients with breast cancer

In ATLAS trial, Davies C et al. randomized 12,894 females with early breast cancer diagnosed and receiving adjuvant tamoxifen to either 10 years continued tamoxifen or 5 years of tamoxifen therapy. The primary goal of the trial was to study breast cancer recurrence and mortality in these patients. The results of the ATLAS trial were significantly in favor of pursuing the 10 years prolong therapy as compared with 5 years. The authors concluded that for women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis. The ATLAS trial proved to be a big breakthrough in terms of practice-changing implications. Source